SKS: validation, formal analysis, investigation, data curation, writing–original draft, visualization. BA: validation, formal analysis, investigation, writing, review and editing, visualization. AD: validation, formal analysis, writing, review and editing, visualization. KB: validation, formal analysis, writing, review and editing, visualization. MK: investigation, data curation, writing–review and editing. MCWW: validation, formal analysis, writing, review and editing, visualization. JSG: validation, formal analysis, writing, review and editing, visualization. AB: formal analysis, writing–review and editing, data curation. NVP: data curation, writing–review and editing. NT: software, formal analysis, data curation, visualization. ISR: validation, resources, formal analysis, writing, review and editing. LVA: conceptualization, methodology, writing– review and editing, supervision. RBD: resources, writing–review editing. CWY, NN and TL: resources. ABS: methodology, formal analysis, resources, writing–review and editing. DK- K: data curation, writing–review and editing. AJ: data curation. DC: conceptualization, methodology, writing–review and editing. JK: conceptualization, methodology, software, writing–review and editing, supervision, funding acquisition. MD: conceptualization, methodology, writing, review and editing, supervision, funding acquisition. SRH: conceptualization, recources, supervision, project administration, funding acquisition. IMS: project administration, conceptualization, methodology, writing, review and editing, supervision, funding acquisition, validation. Funding These works were supported by research grants from Innovation Fond Denmark (7051- 00010B) and the Danish Cancer Society (Knæk Cancer) (R246- A14741- 19- S73). Competing interests MD has received honoraria for lectures from Roche and Novartis (past 2 years). IMS has received honoraria for lectures and consultancies from Novartis, Roche, MSD, BMS, and Pierre Fabre. KB has received honoraria (institutional) for lectures and advisory boards of MSD, Pierre Fabre, and BMS. CCIT- DK has been granted economic support for personal wages from Evaxion Biotech A/S, Denmark. SRH is a cofounder of PokeACell and coinventor of several licensed patents. ABS, DK- K, AJ, NVP , NT and JK are employees of Evaxion Biotech A/S and have a financial interest in the company. All other authors have declared that they have no conflict of interest.